Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Cytomegalovirus Infections 1

Interventions

Peripheral Blood Stem Cell Transplantation 28fludarabine phosphate 25Cyclophosphamide 19Cyclosporine 18Whole-Body Irradiation 17Mycophenolic Acid 17Tacrolimus 15Busulfan 13Antilymphocyte Serum 11Methotrexate 10Methylprednisolone 8Filgrastim 8Vorinostat 7Radiotherapy 7Flow Cytometry 7Etoposide 7Bortezomib 6Psychiatric Rehabilitation 5Everolimus 5Dexamethasone 5Bexarotene 5Alemtuzumab 5Transplantation 4Therapeutics 4Polymerase Chain Reaction 4Panobinostat 4Lenalidomide 4Gemcitabine 4Carboplatin 4Calcium Dobesilate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Sezary Syndrome × letermovir × Clear all
NCT04312841 2025-02-28

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
6 enrolled 11 charts
DermatologicLymphoidOther hematologic neoplasm

Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡